Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

Hawker, Kathleen; O’Connor, Paul; S. Freedman, Mark; A. Calabresi, Peter; P. Antel, Jack; H. Simon, Jack; L. Hauser, Stephen; Waubant, Emmanuelle; Vollmer, Timothy; Panitch, Hillel; Zhang, Jiameng; Chin, Peter; H. Smith, Craig; trial group, OLYMPUS

doi:10.1002/ana.21867

Public

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

Published in Annals of Neurology • Sep 9, 2009

Authors:

Kathleen Hawker

Paul O’Connor

Mark S. Freedman

Abstract

OBJECTIVE: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing-remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks. M...

Subject

Rituximab

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!